Risk factors for discontinuation of pirfenidone in patients with IPF.

(DOCX)</p

Comparison of baseline characteristics and adverse events according to age.

Comparison of baseline characteristics and adverse events according to age.</p

Patient disposition.

Patient disposition.</p

Changes in PFTs according to emphysema and pirfenidone dose.

(a) Changes in FVC in patients with emphysema (p = 0.500); (b) Changes in DLCO in patients with emphysema (p = 0.956); (c) Changes in FVC in patients without emphysema (p = 0.532); (d) Changes in DLCO in patients without emphysema (p = 0.381). Abbreviations: DLCO, diffusing capacity for carbon monoxide; FVC, forced vital capacity.</p

Adverse events in enrolled patients.

Adverse events in enrolled patients.</p

Hospitalization for pneumothorax compared with date of BHD diagnosis.

The figure shows the onset and in-hospital period for pneumothorax per patient. The month zero is defined by the day of BHD diagnosis, and the shaded area is the previous 3 months of the diagnosis. The hospital admission period is depicted as the length of each bar.</p

Factors associated with dose reduction of pirfenidone.

Factors associated with dose reduction of pirfenidone.</p

Emphysema and pulmonary hypertension in patients who underwent serial PFT.

(DOCX)</p

Baseline patient characteristics.

Baseline patient characteristics.</p

Comparison of baseline characteristics and adverse events between patients who continued and discontinued pirfenidone.

Comparison of baseline characteristics and adverse events between patients who continued and discontinued pirfenidone.</p